The Food and Drug Administration said Thursday that it will sharply limit access to the anti- diabetes drug Avandia because of concerns about an increased cardiovascular risk associated with the drug.
Patients who are now taking the drug will have to sign an informed consent statement acknowledging that they understand all the risks before they will be allowed to continue refilling prescriptions.
FDA to limit access to diabetes drug Avandia
